CNRIP1
CB1 cannabinoid receptor-interacting protein 1
Also known as: C2orf32, CNRP1_HUMAN, CRIP1, CRIP1a, CRIP1b, DKFZP566K1924
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96F85
- Gene
- CNRIP1
- Ensembl
- ENSG00000119865
- Chromosome
- 2
- Canonical length
- 164 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
This gene encodes a protein that interacts with the C-terminal tail of cannabinoid receptor 1. Two transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Jul 2013]
Canonical amino-acid sequenceUniProt
164 residues, UniProt reviewed canonical sequence.
>Q96F85|CNRIP1
1 MGDLPGLVRL SIALRIQPND GPVFYKVDGQ RFGQNRTIKL LTGSSYKVEV KIKPSTLQVE
61 NISIGGVLVP LELKSKEPDG DRVVYTGTYD TEGVTPTKSG ERQPIQITMP FTDIGTFETV
121 WQVKFYNYHK RDHCQWGSPF SVIEYECKPN ETRSLMWVNK ESFLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CNRIP1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 75 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 75 nTPM
- hippocampal formation: 61 nTPM
- cerebellum: 61 nTPM
- amygdala: 60 nTPM
- hypothalamus: 52 nTPM
- basal ganglia: 49 nTPM
Single-cell type
- oocytes: 410 nCPM
- megakaryocyte-erythroid progenitors: 191 nCPM
- mast cells: 132 nCPM
- hofbauer cells: 121 nCPM
- erythrocyte progenitors: 90 nCPM
- kupffer cells: 78 nCPM
Immune cell
- basophil: 12 nTPM
- classical monocyte: 0.1 nTPM
- total PBMC: 0.1 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- cerebral cortex: 97 nTPM
- hippocampal formation: 94 nTPM
- basal ganglia: 91 nTPM
- hypothalamus: 72 nTPM
- white matter: 68 nTPM
- cerebellum: 68 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.03
- gnomAD pLI
- 0.16
- gnomAD missense Z
- 0.55
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of signaling receptor activity
- regulation of signaling receptor activity
- regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission
Molecular functions
- type 1 cannabinoid receptor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- CB1 cannabinoid receptor-interacting protein 1
- CB1 cannabinoid receptor-interacting protein 1
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CNRIP1 as an antibody target. Whether an autoantibody or antibody against CNRIP1 could matter depends on whether native CNRIP1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CNRIP1 is annotated at the cell surface, where native CNRIP1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CNRIP1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...